Insider Selling: BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $68,560.80 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Sarah Aebersold sold 2,695 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $25.44, for a total transaction of $68,560.80. Following the transaction, the insider now directly owns 43,165 shares in the company, valued at approximately $1,098,117.60. The trade was a 5.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Sarah Aebersold also recently made the following trade(s):

• On Friday, March 14th, Sarah Aebersold sold 5,632 shares of BioLife Solutions stock. The shares were sold at an average price of $24.96, for a total transaction of $140,574.72.
• On Tuesday, March 11th, Sarah Aebersold sold 1,091 shares of BioLife Solutions stock. The shares were sold at an average price of $25.00, for a total transaction of $27,275.00.
• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The shares were sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Stock Down 1.6 %

BLFS opened at $25.06 on Friday. BioLife Solutions, Inc. has a fifty-two week low of $14.84 and a fifty-two week high of $29.55. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. The firm’s fifty day moving average price is $26.43 and its two-hundred day moving average price is $25.49. The company has a market capitalization of $1.18 billion, a P/E ratio of -23.64 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last issued its earnings results on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The company had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same quarter in the previous year, the company earned ($0.21) EPS. On average, analysts anticipate that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Institutional Investors Weigh In On BioLife Solutions

Institutional investors and hedge funds have recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $26,000. Mark Sheptoff Financial Planning LLC acquired a new stake in shares of BioLife Solutions in the 3rd quarter valued at $28,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of BioLife Solutions in the 4th quarter valued at $31,000. Quest Partners LLC bought a new position in shares of BioLife Solutions in the third quarter valued at about $57,000. Finally, 1620 Investment Advisors Inc. raised its holdings in shares of BioLife Solutions by 41.7% in the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after buying an additional 675 shares during the last quarter. Institutional investors and hedge funds own 93.24% of the company’s stock.

Analysts Set New Price Targets

BLFS has been the topic of a number of recent analyst reports. KeyCorp lifted their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research report on Friday, December 13th. Benchmark reissued a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research report on Thursday, December 19th. StockNews.com raised shares of BioLife Solutions from a “sell” rating to a “hold” rating in a research report on Wednesday. Northland Securities lifted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research report on Wednesday, January 8th. Finally, HC Wainwright lifted their price target on shares of BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, March 6th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.